Delving into the Latest Updates on AD-70 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ADM OXD, ADM-OXD, DOX OXD

+ [4]

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Hematologic NeoplasmsNeoplasms

Originator Organization

Mitsubishi Tanabe Pharma Corp.

Active Organization-

Inactive Organization

Mitsubishi Tanabe Pharma Corp.Mitsubishi Pharma Corp.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of the study is to determine efficacy and safety of combination therapy with adjusted-dose docetaxel-oxaliplatin-capecitabine in patients with advanced gastric adenocarcinoma and intermediate general status.(defined as ECOG 2 or weight loss 10-25% or older that 70 years and no comorbidities nor functional dependency nor geriatric syndrome)

Start Date01 Nov 2008

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

[+1]

100 Clinical Results associated with AD-70

Login to view more data

100 Translational Medicine associated with AD-70

Login to view more data

100 Patents (Medical) associated with AD-70

Login to view more data

12

Literatures (Medical) associated with AD-70

01 Jan 2011·Immunological InvestigationsQ3 · MEDICINE

Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) Modulates Immune Responses toAspergillus fumigatusDuring Fungal Asthma in Mice

Q3 · MEDICINE

Article

Author: Xing, Zhou ; Choi, Esther S. ; Ramaprakash, Hemanth ; Hartl, Dominik ; Murray, Lynne A. ; Buckland, Karen F. ; Aoki, Naoko ; Hogaboam, Cory M. ; Carpenter, Kristin J. ; Lukacs, Nicholas W. ; Kunkel, Steven L.

Triggering receptor expressed on myeloid cells-1 (TREM-1) expression is increased during pulmonary fungal infection suggesting that this receptor might be involved in anti-fungal immune responses. To address the role of TREM-1 in a murine model of fungal allergic airway disease, A. fumigatus-sensitized CBA/J mice received by intratracheal injection a mixture of live A. fumigatus conidia and one of a control adenovirus vector (Ad70), an adenovirus containing a gene encoding for the extracellular domain of mouse TREM-1 and the F(c) portion of human IgG (AdTREM-1Ig; a soluble inhibitor of TREM-1 function), or an adenovirus containing mouse DAP12 (AdDAP12; DAP12 is an intracellular adaptor protein required for TREM-1 signaling), and examined at various days after challenge. Whole lung TREM-1 levels peaked at day 3 whereas circulating TREM-1 levels peaked at day 30 in this fungal asthma model. AdTREM-1Ig-treated mice exhibited significantly higher airway hyperresponsiveness following methacholine challenge compared with Ad70- and AdDAP12-treated mice. Whole lung analysis of AdTREM-1Ig treated mice revealed markedly higher amounts of fungal material compared with the other groups. ELISA analysis of whole lung and bronchoalveolar lavage samples indicated that several pro-allergic cytokine and chemokines including CCL17 and CCL22 were significantly increased in the AdTREM-1Ig group compared with the other groups. Finally, Pam3Cys and soluble Aspergillus antigens induced TREM-1 transcript expression in macrophages in a TLR2 dependent manner. In conclusion, TREM-1 modulates the immune response directed against A. fumigatus during experimental fungal asthma.

01 Jun 2009·International Journal of PharmaceuticsQ2 · MEDICINE

A smart flower-like polymeric micelle for pH-triggered anticancer drug release

Q2 · MEDICINE

Article

Author: Eun Seong Lee ; Kyung Taek Oh ; Don Haeng Lee ; Young Taik Oh ; Kwangmyung Kim ; Nam-Muk Oh

Novel pH-responsive flower-like micelles were developed to provide the mechanism for pH-triggered drug release from drug carriers. The micelles (particle size: approximately 165 nm; critical micelle concentration (CMC): approximately 4 microg/ml), constructed from poly(N(epsilon)-(3-diethylamino)propyl isothiocyanato-L-lysine)-b-poly(ethylene glycol)-b-poly(L-lactide) [poly(DEAP-Lys)-b-PEG-b-PLLA], were designed to have a self-assembled flower-like arrangement consisting of two hydrophobic blocks [deprotonated poly(DEAP-Lys) block and PLLA block] and a petal-like hydrophilic PEG block at physiological pH. As the pH decreases to slightly acidic pH (

26 Sep 2006·ChemInform

Synthesis, Physicochemical Characterization and Preliminary Pharmacological in vitro Evaluation of Two Novel Cytotoxic Benzophenone‐Linked 3,3‐Dimethyltriazenes.

Article

Author: G Momekov ; I Manolov ; H J Machulla

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

100 Deals associated with AD-70

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 1	-	Mitsubishi Tanabe Pharma Corp.	-
Neoplasms	Phase 1	Japan	Mitsubishi Pharma Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2021	Not Applicable	Renal Cell Carcinoma	16	Gemcitabine plus doxorubicin (Gem + Dox)	pgdtxknhuc(zwdastgogn) = no grade ≥ 2 reported events of cardiotoxicity uauvosofgj (djsosnmnhy ) View more	-	02 Mar 2021
ASCO_GI2020	Not Applicable	Adenocarcinoma	28	Perioperative DOX	(fppblsbwvf) = wsjjjbvfle lkeajgyuug (sejuxodmxe )	Positive	04 Feb 2020
AACR2015	Not Applicable	Breast Cancer	-	DOX-lipid conjugate	tiqiljpbjb(qcluutpmdu) = qkcozfaiwt bllhkdxqeq (mqtaeyiduh )	-	01 Aug 2015
ASCO2015	Not Applicable	Sarcoma First line	41	Metastatic STS patients receiving single agent dox.	lmzlzeeusx(ydugpvwlmp) = wzciodkxew mgcscbeugx (rtotgkducr )	-	20 May 2015
ASCO2015	Not Applicable	Osteosarcoma	26	CP and DOX	(yokinmoqnw) = xstdkbavzg lcfjunyuza (qdkoxewfzu ) View more	-	20 May 2015
ASCO2015	Not Applicable	Osteosarcoma	26	CP, DOX, and HDM	(yokinmoqnw) = wgiblqaykj lcfjunyuza (qdkoxewfzu ) View more	-	20 May 2015
ASCO2005	Phase 2/3	Hepatocellular Carcinoma	339	T138067 250 mg/m2	(sixwwcogpw) = ispjvaudbb hksdesoixm (usgeoaexst )	Negative	01 Jun 2005
ASCO2005	Phase 2/3	Hepatocellular Carcinoma	339	DOX 60 mg/m2	(sixwwcogpw) = wwlkhbagbr hksdesoixm (usgeoaexst )	Negative	01 Jun 2005